Mr. Bill Zhang reports

DRI HEALTHCARE TRUST ANNOUNCES CLOSING OF US$250 MILLION OF SENIOR SECURED NOTES

DRI Healthcare Trust's subsidiary, DRI Healthcare LP, has successfully closed its previously announced private placement offering, consisting of two tranches of senior secured notes:

• $106-million (U.S.) aggregate principal amount of 5.35 per cent senior secured notes due March 24, 2031;
• $144-million (U.S.) aggregate principal amount of 5.65 per cent senior secured notes due March 24, 2033.

Interest on the notes is payable semi-annually, and the notes rank pari passu with the issuer's existing amended and restated credit agreement, and are secured by substantially all the assets of DRI Healthcare and its subsidiaries. The net proceeds of this offering are intended to be used to repay outstanding debt, to pay related fees and expenses, and for general corporate purposes.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, DRI Healthcare has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.

We seek Safe Harbor.